124 related articles for article (PubMed ID: 23445758)
1. [Current and future indications for bendamustine: chronic lymphocytic leukemia, indolent lymphoma, mantle cell lymphoma and diffuse large B-cell lymphomas].
Hallek M; Knauf W; Dreyling M; Trümper L
Onkologie; 2013; 36 Suppl 1():11-8. PubMed ID: 23445758
[No Abstract] [Full Text] [Related]
2. Bendamustine's emerging role in the management of lymphoid malignancies.
Rummel MJ; Gregory SA
Semin Hematol; 2011 Apr; 48 Suppl 1():S24-36. PubMed ID: 21530769
[TBL] [Abstract][Full Text] [Related]
3. Bendamustine in chronic lymphocytic leukemia and refractory lymphoma.
Rummel MJ
Semin Hematol; 2008 Jul; 45(3 Suppl 2):S7-10. PubMed ID: 18760709
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine: a new look at an old drug.
Kalaycio M
Cancer; 2009 Feb; 115(3):473-9. PubMed ID: 19117340
[TBL] [Abstract][Full Text] [Related]
5. Therapy-related acute myeloid leukemia in a patient with chronic lymphocytic leukemia treated with rituximab-bendamustine.
García-Muñoz R; García DK; Roldán-Galiacho V; Merchante-Andreu M; Campeny-Najara A; Rabasa P
Ann Hematol; 2014 Apr; 93(4):699-702. PubMed ID: 23907409
[No Abstract] [Full Text] [Related]
6. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
7. Single centre study of using bendamustine in the treatment of B-cell malignancies.
Osmani AH; Masood N
J Pak Med Assoc; 2013 Jun; 63(6):702-6. PubMed ID: 23901668
[TBL] [Abstract][Full Text] [Related]
8. Bendamustine in the treatment of chronic lymphocytic leukemia.
Knauf W
Expert Rev Anticancer Ther; 2009 Feb; 9(2):165-74. PubMed ID: 19192955
[TBL] [Abstract][Full Text] [Related]
9. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel.
Cheson BD; Wendtner CM; Pieper A; Dreyling M; Friedberg J; Hoelzer D; Moreau P; Gribben J; Knop S; Montillo M; Rummel M
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):21-7. PubMed ID: 20223726
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic strategies in multiple myeloma: the future role of bendamustine].
Goldschmidt H; Kropff M; Mügge LO; Pönisch W
Onkologie; 2013; 36 Suppl 1():19-26. PubMed ID: 23445759
[No Abstract] [Full Text] [Related]
11. [Toxicodermia by bendamustine: development of a desensization protocol].
Sangrador Pelluz C; Luis Hidalgo MM; Martínez García M; Pérez-Serrano Lainosa MD; Soler Company E
Farm Hosp; 2013; 37(5):421-3. PubMed ID: 24128107
[No Abstract] [Full Text] [Related]
12. Bendamustine: inadequate or outdated data.
Prescrire Int; 2012 Mar; 21(125):64. PubMed ID: 22428184
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
Sanchez-Gonzalez B; Peñalver FJ; Medina A; Guillén H; Calleja M; Gironella M; Arranz R; Sebastian E; de Oña R; Cánovas A; de la Fuente I; Grande C; Sancho JM; Perez R; Domingo E; Lopez-Lorenzo JL; Prieto E; Panizo C; Gorosquieta A; Perez I; Cervera JM; Marin M; Mencha C; Ramila E; Salar A
Leuk Res; 2012 Jun; 36(6):709-14. PubMed ID: 22154023
[TBL] [Abstract][Full Text] [Related]
14. Bendamustine (Treanda) for CLL and NHL.
Med Lett Drugs Ther; 2008 Nov; 50(1299):91-2. PubMed ID: 19008789
[No Abstract] [Full Text] [Related]
15. Letter from the editor.
Cheson BD
Clin Adv Hematol Oncol; 2012 Oct; 10(10):632. PubMed ID: 23187769
[No Abstract] [Full Text] [Related]
16. [II. Treatment trend and outlook on bendamustine for mantle cell lymphoma and follicular lymphoma].
Ogura M
Gan To Kagaku Ryoho; 2012 May; 39(5):736-42. PubMed ID: 22701900
[No Abstract] [Full Text] [Related]
17. Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemia.
Haskova Z; Whitacre MN; Dede KA; Lee JM; Trulli SH; Ciucci M; Toso JF; White JR; Jonak ZL
Br J Haematol; 2012 Feb; 156(3):402-4. PubMed ID: 21848524
[No Abstract] [Full Text] [Related]
18. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
Roué G; López-Guerra M; Milpied P; Pérez-Galán P; Villamor N; Montserrat E; Campo E; Colomer D
Clin Cancer Res; 2008 Nov; 14(21):6907-15. PubMed ID: 18980985
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Ujjani C; Cheson BD
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1353-65. PubMed ID: 20836669
[TBL] [Abstract][Full Text] [Related]
20. Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group.
Cuneo A; Marchetti M; Barosi G; Billio A; Brugiatelli M; Ciolli S; Laurenti L; Mauro FR; Molica S; Montillo M; Zinzani P; Tura S
Leuk Res; 2014 Nov; 38(11):1269-77. PubMed ID: 25063524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
